RT @Yuz6Yusof: 2022 has been a great year for development of novel therapies in Phase 2 RCTs in #lupus as highlighted by

Social Author Image
https://pbs.twimg.com/profile_images/1577637763561783296/TMmRRqmv.jpg
Tweet Author
Yuz6Yusof
Social Author Name
Md Yuzaiful Md Yusof
Tweet Content
2022 has been a great year for development of novel therapies in Phase 2 RCTs in #lupus as highlighted by Dr Langford #ACR22 Year In Review. I'd add Deucravacitinib to those lists. Look forward to Phase 3 results soon @RheumNow https://t.co/yH25KFDGdd
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.